Life

skynesher/E+ via Getty Images Lantheus Holdings (NASDAQ:LNTH) Thursday announced its acquisition of the global rights of Life Molecular Imaging’s RM2, targeting the gastrin-releasing peptide receptor, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair. This acquisition strengthens Lantheus’ (LNTH) presence in prostate cancer and expands its pipeline to include breastContinue Reading